Technology update: bronchoscopic thermal vapor ablation for managing severe emphysema

Area of Science:

• Pulmonology
• Interventional Pulmonology
• Respiratory Medicine

Background:

• Severe emphysema, particularly upper lobe-predominant, significantly impacts lung function and quality of life.
• Lung volume reduction therapy aims to alleviate symptoms and improve outcomes in these patients.
• Bronchoscopic thermal vapor ablation (BTVA) is an emerging endoscopic therapeutic option.

Purpose of the Study:

• To review the Bronchoscopic thermal vapor ablation (BTVA) procedure for treating severe emphysema.
• To elucidate the mechanism of action of BTVA.
• To summarize the efficacy and safety data from clinical trials of BTVA.

Main Methods:

• Review of existing clinical single-arm trials and literature on BTVA.
• Analysis of the procedure, including heated water vapor instillation.
• Evaluation of induced inflammatory response, fibrosis, and subsequent lobar volume reduction.

Main Results:

• BTVA demonstrated significant improvements in lung function, exercise capacity, and quality of life.
• The procedure involves inducing an inflammatory response leading to lung parenchyma fibrosis and lobar volume reduction.
• Transient clinical worsening may occur due to the inflammatory response, necessitating strict patient monitoring.

Conclusions:

• BTVA is an effective endoscopic lung volume reduction therapy for severe upper lobe-predominant emphysema.
• Balancing the efficacy and safety of BTVA will be a key challenge for future clinical application.
• Further research and monitoring are essential to optimize BTVA outcomes.